Hazar, VolkanKesik, VuralKarasuc, Gulsun TezcanOzturk, GulyuzKupesiz, AlphanKilic, Suar CakiAtas, ErmanUygun, VedatEker, NursahErbey, FatihBengoa, Sebnem YilmazEmir, SunaAnak, SemaOniz, HaldunDaloglu, HayriyeAksoylar, SerapKocak, UlkerKarakukcu, MusaElli, MuratKurucu, NilgunYesilipek, Akif c2019-10-272019-10-2720181042-81941029-2403https://doi.org/10.1080/10428194.2017.1330472https://hdl.handle.net/11454/31377We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemosensitive disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p <. 001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.en10.1080/10428194.2017.1330472info:eu-repo/semantics/closedAccessRelapsed or refractory non-Hodgkin lymphomachildren and adolescentshematopoietic stem cell transplantationArticle5918596WOS:00041211880001028571522Q2Q3